InflaRx to Proceed With Skin-Disease Drug Study After FDA Meeting

 InflaRx NV said it would proceed with its study of the use of vilobelimab to treat hidradenitis suppurativa, a skin disease, following a meeting with the Food and Drug Administration about its development program.

In the meeting, the FDA's response to InflaRx's proposals for the study's design supported a primary efficacy endpoint that would measure three types of lesions: inflammatory nodules, abscesses and draining tunnels. The study program would focus on patients with active draining tunnels, a symptom that accompanies HS.

The disease brings inflammation of hair follicles on the body, leading to pus formation.

InflaRx said it is still discussing final study-design details with the FDA.

https://www.marketscreener.com/quote/stock/INFLARX-N-V-38607083/news/InflaRx-to-Proceed-With-Skin-Disease-Drug-Study-After-FDA-Meeting-36372526/